Table 2.

Hematologic and Cytogenetic Responses After a Median of 14 Months of Follow-Up

Response	All Patients (N = 174)		Imatinib Status				Stem-Cell Transplantation				Prior BCR-ABL Mutation*
			Patients With Imatinib-Resistant Disease (n = 161)		Imatinib-Intolerant Patients (n = 13)		Prior SCT (n = 23)		No Prior SCT (n = 151)		Any Mutation (n = 88)		P-Loop Mutation (n = 34)		No Mutation (n = 68)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Hematologic	138	79	126	78	12	92	18	78	120	80	74	84	28	82	50	74
Major HR	111	64	102	63	9	69	15	65	96	64	64	73	24	71	38	56
95% CI, %	56 to 71		55 to 71		39 to 91		43 to 84		55 to 71		62 to 82		53 to 85		43 to 68
CHR	78	45	72	45	6	46	12	52	66	44	48	55	20	59	23	34
95% CI, %	37 to 53		37 to 53		19 to 75		31 to 73		36 to 52		44 to 65		41 to 75		23 to 46
NEL	33	19	30	19	3	23	3	13	30	20	16	18	4	12	15	22
No hematologic response	36	21	35	22	1	8	5	22	31	20	14	16	6	18	18	26
Cytogenetic
MCyR	67	39	62	39	5	39	6	26	61	40	35	40	11	32	27	40
95% CI, %	31 to 46		31 to 46		14 to 68		10 to 48		32 to 49		29 to 51		17 to 51		28 to 52
CCyR	55	32	50	31	5	39	4	17	51	34	28	32	9	26	22	32
95% CI, %	25 to 39		24 to 39		14 to 68		5 to 39		26 to 42		22 to 43		13 to 44		22 to 45
PCyR	12	7	12	8	0	0	2	9	10	7	7	8	2	6	5	7
Minor CyR	10	6	10	6	0	0	1	4	9	6	4	5	2	6	5	7

Abbreviations: SCT, stem-cell transplantation; CCyR, complete cytogenetic response; CHR, complete hematologic response; CyR, cytogenetic response; HR, hematologic response; MCyR, major cytogenetic response; NEL, no evidence of leukemia; PCyR, partial cytogenetic response.

^*Mutation data available in 156 patients.